Latest Thyroid neoplasm Stories
By Montone, Kathleen T Baloch, Zubair W; LiVolsi, Virginia A Context.-Hurthle cells are eosinophilic, follicular-derived cells that are associated with a variety of nonneoplastic and neoplastic thyroid lesions. The differential diagnosis of Hurthle cell lesions is quite broad.
Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK.
By Megan Williams, The Free Lance-Star, Fredericksburg, Va. Jul. 27--When Anita Kaissi found herself feeling constantly sluggish, she thought it was because she had just had a baby.
San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial.
Exelixis has initiated the Phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer.
Exelixis, Inc. (Nasdaq:EXEL) announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. XL184 is a small molecule anticancer compound targeting the MET, RET, and VEGFR2 receptor tyrosine kinases.
WALTHAM, Mass., July 17, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc.
By Fisher, Ronald E Siegel, Barry A; Edell, Steven L; Oyesiku, Nelson M; Morgenstern, David E; Messmann, Richard A; Amato, Robert J ^sup 99m^Tc-EC20 is a folate receptor (FR)-targeted imaging agent consisting of the vitamin folate conjugated to ^sup 99m^Tc.
SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and the U.S.
A new European study published this week surmises that weight gain increases the risk of developing most types of cancer.
- Emitting flashes of light; glittering.